

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet	1	of	1
-------	---	----	---

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

[illegible][illegible]

Examiner  
Signature

Date  
Considered

1218105

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\* already considered on 9/2/05 LOS RB

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/822,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

Sheet 1 of 5

## U.S. PATENT DOCUMENTS

Sequence Number Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
1		5,622,977		Warrellow et al.	04/22/1997	
2		5,633,257		Warrellow et al.	05/27/1997	
3		5,679,696		Fenton et al.	10/21/1997	
4		5,693,659		Head et al.	12/02/1997	
5		5,698,711		Palfreyman	12/16/1997	
6		5,710,160		Guay et al.	01/20/1998	
7		5,710,170		Guay et al.	01/20/1998	
8		5,712,298		Amschler	01/27/1998	
9		5,723,460		Warrellow et al.	03/03/1998	
10		5,728,712		Montana et al.	03/17/1998	
11		5,739,144		Warrellow et al.	04/14/1998	
12		5,776,958		Warrellow et al.	07/07/1998	
13		5,780,477		Head et al.	07/14/1998	
14		5,780,478		Alexander et al.	07/14/1998	
15		5,786,354		Warrellow et al.	07/28/1998	
16		5,798,373		Warrellow et al.	08/25/1998	
17		5,840,724		Fenton et al.	11/24/1998	
18		5,849,770		Head et al.	12/15/1998	
19		5,859,034		Warrellow et al.	01/12/1999	
20		5,891,896		Warrellow et al.	04/06/1999	
21		5,866,593		Warrellow et al.	02/02/1999	
22		5,919,937		Lynch et al.	07/06/1999	
23		5,935,978		Fenton et al.	08/10/1999	
24		5,962,483		Warrellow et al.	10/05/1999	
25		5,962,492		Warrellow et al.	10/05/1999	
26		6,077,854		Warrellow et al.	06/20/2000	
27		5,814,651		Duplantier et al.	09/29/1998	
28		6,255,326		Ashton et al.	07/03/2001	
29		6,096,768		Ashton et al.	08/01/2000	
30		6,162,830		Connor et al.	12/19/2000	
31		6,180,650		Frenette et al.	01/30/2001	
32		6,240,593		Cote et al.	03/13/2001	

Examiner  
Signature

Robert Apple

Date  
Considered

10/18/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete If Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>RA</i>		6,204,275		Friesen et al.	03/20/2001	
<i>RA</i>		6,245,774		Warrellow et al.	06/12/2001	
<i>RA</i>		6,297,264		Head et al.	10/02/2001	
<i>RA</i>	1	5,880,135			3/9/1999	
<i>RA</i>	2	6,262,040			7/17/2001	
<i>RA</i>	3	6,040,329			3/21/2000	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>3</sub>
		Office <sup>2</sup>	Number <sup>4</sup> (if known)				
<i>RA</i>		FR	2729142	A1	Nadler et al.	07/12/1996	
<i>RA</i>		EP	1116711	A2	Chassot et al.	07/18/2001	
<i>RA</i>		EP	0994100	A1	Shinji et al.	04/19/2000	
<i>RA</i>		WIPO	00/71129	A1	Hunt et al.	11/30/2000	
<i>RA</i>		WIPO	94/27971	A1	Nadler et al.	12/08/1994	
<i>RA</i>		WIPO	93/25517			12/23/1993	
<i>RA</i>		WIPO	94/14742			07/07/1994	
<i>RA</i>		WIPO	98/58901			12/30/1998	
<i>RA</i>		JP	11-189577			07/13/1999	
<i>RA</i>		WIPO	96/23754			08/08/1996	
<i>RA</i>		WIPO	99/33806		John et al.	07/1999	
<i>RA</i>		WIPO	96/36620		Giulio et al.	11/1996	
<i>RA</i>		WO	00/04874			11/2/00	
<i>RA</i>		WO	01/70738			9/27/01	
<i>RA</i>		WO	94/02465			2/3/94	
<i>RA</i>		WO	95/01338			1/12/95	
<i>RA</i>		JP	2001 11047			1/16/2001	
<i>RA</i>		WO	02 059110	PCT		8/1/2002	
<i>RA</i>		WO	97 00868	PCT		1/5/1997	1
<i>RA</i>		WO	98 09961	PCT		3/12/1998	2
<i>RA</i>		WO	97 49702	PCT		12/31/1997	3
<i>RA</i>		WO	00 69841	PCT		11/23/2000	

Examiner Signature

*Kelvin Anderson*

Date Considered

12/8/05

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 10 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

already considered on 8/16/05 JDS RA

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page 3 of 5

## Complete If Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
Rb		HEILMAN et al, "Synthesis and Antinflammatory Evaluation of Substituted Isophthalonitriles, Trimesonitriles, Benzonitriles, and Terephthalonitriles", Journal of Medicinal Chemistry, 1978, Vol. 21, No. 9, pp. 906-913, XP-00226236	
Rb		WATANABE et al, "Structure-Activity Relationship and Rational Design of 3,4-Dephosphatins Derivatives as Protein Tyrosine Phosphatase Inhibitors", Pergamon Tetrahedron, 2000, Vol. 56, pp. 741-752	
Rb		INOUE et al, "Steric Tuning in Chiral Ligand Mediated Enantioselective Alkylation of Imines", Tetrahedron: Asymmetry, 1993, Vol. 4, No. 7, pp. 1603-1606, XP002226237	
Rb		THOMAS C. MCKENZIE et al., "The Gomberg-Bachmann Reaction of Purines", J. Heterocyclic Chem., May-Jun 1987, pp. 859-861, Vol. 24	
Rb		VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," J. Am. Chem. Soc., 1989, pp. 8502-8504, Vol. 111	
Rb		VASU NAIR et al., "Synthesis Of Congeners Of Adenosine Resistant To Deamination By Adenosine Deaminase," J. Chem. Soc Comm., 1989, pp. 878-879	
Rb		JAMES L. KELLEY et al., "Synthesis and Structure- Activity Relationships of 2-Substituted-6-(dimethylamino)- 9-(4-methylbenzyl)-9H-purines with Antirhinovirus Activity," J. Med. Chem., 1989, pp. 218-224, Vol. 32	
Rb		JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," Eur. J. Med. Chem., 1990, pp. 131-135, Vol. 25	

Examiner Signature

*Rebeccah Jordan*

Date Considered

12/18/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 041-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

## Complete If Known

Application Number	10/622,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Docket Number	MEMORY-28

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Rd		ROGER J. SCHILLING et al., "A High-Throughput Assay For Cyclic Nucleotide Phosphodiesterases," <i>Analytical Biochemistry</i> , 1994, pp.154-158, Vol. 215	
Rb		DONALD V. DANIELS et al., "A Semiautomated Method for the Assay of Cyclic Adenosine 5'-Monophosphate Phosphodiesterase," <i>Analytical Biochemistry</i> , 1996, pp. 367-369, Vol. 236	
Rb		JEAN-JACQUES BOURGUIGNON et al., "9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors," <i>J. Med. Chem.</i> , 1997, pp. 1768-1770, Vol. 40	
Rb		JAMES L. KELLEY et al., "6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," <i>J. Med. Chem.</i> , 1997, pp. 3207-3216, Vol. 40	
Rb		HIROYUKI SAWANISHI et al., "Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines," <i>J. Med. Chem.</i> , 1997, pp. 3248-3253, Vol. 40	
Rb		J.E. SOUNNES et al., "Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases," <i>Cell Signal</i> , 1997, pp. 227-236, Vol. 9, No. 3-4	
Rb		MARY ELIZABETH BACH et al., "Age-related deficits in spatial memory are correlated with defects in the late phase of hippocampal long term potentiation in vivo and are attenuated by drugs that enhance the cAMP signaling pathway," <i>Proc. Natl. Acad. Sci. USA</i> , April 1999, pp.5280-5285, Vol. 96	
Rb		ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9-Benzyladenine," <i>The Journal Of Pharmacology And Experimental Therapeutics</i> , 2000, pp. 647-653, Vol. 292, No.2	
Rb		Anil S. GURAM et al., "A Simple Catalytic Method for the conversion of Aryl Bromides to Arylamines," <i>Angew. Chem. Int. Ed. Engl.</i> , 1995, Vol. 34, No. 12, pp. 1348-1350.	
Rb		Michael S. DRIVER et al., "A Second-Generation Catalyst for the Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdCl <sub>2</sub> ," <i>J. Am. Chem. Soc.</i> , 1996, Vol. 118, pp. 7217-7218.	
Rb		Takashi EGAWA et al., "Rolipram and its Optical Isomers, Phosphodiesterase 4 Inhibitors, Attenuated the Scopolamine-Induced Impairments of Learning and Memory in Rats," <i>J. Pharmacol.</i> , Vol. 75, 275-281(1997).	
Rb		Peng WANG et al., "Expression, Purification, and Characterization of Human cAMP-Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D," <i>Biochem. And Biophys. Research Comm.</i> , Vol. 234, 320-324 (1997).	

Examiner  
Signature

Robert Jones

Date  
Considered

12/18/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

## Complete If Known

Application Number	10/822,833
Filing Date	July 21, 2003
First Named Inventor	Richard A. SCHUMACHER et al
Group Art Unit	Unassigned 1626
Examiner Name	Unassigned
Attorney Pocket Number	MEMORY-28

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
RL		JAMES F. KELLEY et al., "Anticholinergic structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <i>Eur. J. Med. Chem.</i> , 1990, pp. 131-135, Vol. 25	
RL		Domine M. T. CHAN et al., "New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate," <i>Tetrahedron Letters</i> , Vol. 39, 2933-2936 (1998).	
RL		Mark BARAD et al., "Rolipram, a Type IV-Specific Phosphodiesterase Inhibitor Facilitates the Establishment of Long-lasting Long-term Potentiation and Improves Memory," <i>Proc. Natl. Acad. Sci.</i> , Vol. 95, pp. 15020-15025 (December 1998).	
RL		Miles D. HOUSLAY et al., "The Multienzyme PDE4 Cyclic Adenosine Monophosphate-Specific Phosphodiesterase Family: Intracellular Targeting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions," <i>Advances in Pharmacology</i> , Vol. 44, pp. 225-342, 1998.	
RL		John HARTWIG et al., "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand," <i>J. Org. Chem.</i> , 1999, Vol. 64, pp. 5575-5580.	
RL		Han-Ting ZHANG et al., "Inhibition of Cyclic AMP Phosphodiesterase (PDE4) Reverses Memory Deficits Associated with NDMA Receptor Antagonism," <i>Neuropsychopharmacology</i> , 2000, Vol. 23, pp. 198-204.	
RL		Han-Ting ZHANG et al., "Effects of Rolipram on Scopamine-induced Impairment of Working and Reference Memory in the Radial-arm Maze tests in Rats," <i>Psychopharmacology (Berl)</i> 2000 June;150(3):pp. 311-6.	
RL		T.W. Greene et al., <i>Protective Groups in Organic Synthesis</i> , 3 <sup>rd</sup> Edition, Chapter 3, "Protection for Phenols and Catechols," pp. 246-292, John Wiley & Sons, 1999	
/RA/		International Search Report from PCT Application No. PCT/US02/01508, dated January 16, 2003	

Examiner Signature	<i>Katherine J. Anderson</i>	Date Considered	12/8/06
--------------------	------------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.